Geode Capital Management
CERE

Geode Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Geode Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,469,670
Closed -$60.1M – 4644
2024
Q2 		$60.1M Sell
1,469,670
-404,717
-22% -$16.9M 0.01% 1229
2024
Q1 		$79.2M Buy
1,874,387
+85,085
+5% +$3.57M 0.01% 1076
2023
Q4 		$75.9M Buy
1,789,302
+350,025
+24% +$10.1M 0.01% 1050
2023
Q3 		$31.4M Buy
1,439,277
+93,248
+7% +$2.33M ﹤0.01% 1532
2023
Q2 		$42.8M Buy
1,346,029
+88,109
+7% +$2.7M 0.01% 1355
2023
Q1 		$30.7M Buy
1,257,920
+53,812
+4% +$1.58M ﹤0.01% 1519
2022
Q4 		$38M Buy
1,204,108
+69,847
+6% +$1.97M 0.01% 1342
2022
Q3 		$32.1M Buy
1,134,261
+81,971
+8% +$2.44M ﹤0.01% 1404
2022
Q2 		$27.8M Buy
1,052,290
+126,589
+14% +$3.59M ﹤0.01% 1519
2022
Q1 		$32.4M Sell
925,701
-3,072
-0.3% -$89.7K ﹤0.01% 1561
2021
Q4 		$30.1M Buy
928,773
+19,658
+2% +$694K ﹤0.01% 1694
2021
Q3 		$26.8M Buy
909,115
+156,688
+21% +$4.4M ﹤0.01% 1754
2021
Q2 		$19.3M Buy
752,427
+308,636
+70% +$4.42M ﹤0.01% 1990
2021
Q1 		$6.09M Sell
443,791
-14,992
-3% -$219K ﹤0.01% 2686
2020
Q4 		$7.61M Buy
+458,783
New +$5.96M ﹤0.01% 2343

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Geode Capital Management's CERE Position: Q3 2024 in Review

Geode Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,469,670 shares — an estimated $60.1M sold.

Geode Capital Management first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $79.2M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Geode Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Geode Capital Management sold 1,469,670 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $60.1M.
  • Geode Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Geode Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $79.2M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.